COMPANY:

MGI Tech

"MGI Tech Co., Ltd. ("MGI")...established a partnership with Oncoclínicas&Co, through OC Medicina de Precisão, which comprises Genomics, Pathology and Big Data laboratories, to expand access to cutting-edge genomic tests and strengthen diagnostic capabilities in the field of oncology in Brazil." "

"MGI Tech Co., Ltd...announced a commercial partnership with Human Cell Atlas (HCA) consortium to further accelerate the human cell mapping initiative. Aimed to facilitate the wider adoption of single cell sequencing and spatial transcriptomics technologies globally, MGI will expand access to its proprietary products within the HCA network by providing discounted rates to collaborating members."

"MGI Tech Co., Ltd....announced the collaboration with OncoDNA, a genomic and theranostic company specializing in precision medicine for the treatment of cancer and genetic diseases. The OncoDEEP® Kit’s comprehensive workflow—encompassing sequencing, secondary analysis, and final interpretation of NGS data (OncoKDM™) —is now fully compatible with MGI sequencers."

"MGI Tech Co., Ltd...has just formed a strategic alliance with Dasa...to expand Brazilian patients' access to next-generation genomics and promote significant advancements in Brazil's healthcare sector...New technologies will contribute to performing genetic tests to diagnose cancers, rare diseases and other diseases with greater precision, advancing personalized medicine in the country..."

"MGI...today announced a collaboration with Predica Diagnostics, a leading innovator in oncology diagnostics, to develop Predica’s targeted RNA sequencing tests on MGI’s cost-effective next-generation sequencing platforms....The collaboration aims to revolutionize molecular diagnostics by enabling early detection of cancer and facilitating personalized targeted treatment strategies. By combining Predica Diagnostics’ advanced sequencing assays with MGI’s cutting-edge next-generation sequencing platforms, the initiative promises a fast, accurate and affordable solution for healthcare providers."

"MGI...is thrilled to announce a strategic partnership with Gencell...This collaboration capitalizes on the expertise and established market presence of Gencell and integrates MGI's state-of-the-art sequencers based on DNBSEQ technology, to enhance data analysis capabilities...By merging respective strengths and expertise, MGI and Gencell are committed to expediting the adoption of cutting-edge sequencing technologies and advancing superior patient care throughout the region."

"MGI Tech...entered a research partnership with National Cancer Centre Singapore (NCCS) to facilitate genomic profiling of Asian-prevalent cancers...Under the partnership, MGI's DNBSeq-G400 sequencer will be used at NCCS' Cancer Discovery Hub (CDH) for RNA sequencing to help study certain Asian-prevalent cancers, such as head and neck, ovary, and breast cancers."